Clinical Trials
25
Trial Phases
5 Phases
Drug Approvals
24
Drug Approvals
Saccharomyces boulardii capsules
- Product Name
- 亿活
- Approval Number
- 国药准字SJ20150052
- Approval Date
- Jul 28, 2020
Saccharomyces boulardii sachets
- Product Name
- 亿活
- Approval Number
- 国药准字SJ20150051
- Approval Date
- Jul 12, 2020
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
The Effect of Mucogyne® Ovule on Wound Healing (ORIGYNE)
- Conditions
- Cervicovaginitis
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 144
- Registration Number
- NCT06585579
- Locations
- 🇫🇷
CHU Amiens-Picardie, Amiens, France
🇫🇷CHU Besançon, Besançon, France
🇫🇷Hôpital Nord Franche-Comté, Trévenans, France
Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3
- Conditions
- Primary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2Primary Hyperoxaluria Type 3
- Interventions
- Drug: Placebo Oral CapsuleBiological: Urine samples collectBiological: Blood samples collectOther: Kidney imagingOther: Quality of Life questionnaires
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 42
- Registration Number
- NCT06465472
Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (early Skin Form of Lyme Borreliosis))
- Conditions
- Erythema Migrans of Lyme Disease
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 120
- Registration Number
- NCT06451913
Performance and Safety of MUCOGYNE® Ovule as a Moisturizer
- Conditions
- Vaginal Dryness
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 33
- Registration Number
- NCT06282614
- Locations
- 🇫🇷
JEAN Christian's medical office, Nogent-sur-Marne, France
🇫🇷Dr Ramez GHADRI's medical office, Orléans, France
🇫🇷Dr Raïssa APERANO-MAS's medical office, Rennes, France
Evaluation of the Efficacy and Safety of Mucogye® Gel as a Moisturizer
- Conditions
- Vaginal Dryness
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 50
- Registration Number
- NCT05913479
- Locations
- 🇫🇷
Dr Paul Lefevre's medical office, Caen, France
🇫🇷Dr Thierry KELLER's medical office, Colmar, France
🇫🇷Sihame MOKHBAT's office, Paris, France
- Prev
- 1
- 2
- 3
- 4
- Next
News
Global Clinical Trials for Dravet Syndrome Reviewed in 2024
• A new report offers an overview of the clinical trial landscape for Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy, providing key data and analysis. • The review includes data on trial numbers, average enrollment, and top countries involved, segmented by region, phase, status, endpoints, and sponsor type. • Key companies like Jazz Pharmaceuticals, UCB, Takeda, and others are profiled, with details on their ongoing trials and prominent drugs in development for Dravet Syndrome. • The report identifies trends in clinical trial enrollment over the past five years and highlights recent news related to Dravet Syndrome research and development.